Cannabidiol (CBD) is generating increasing interest in France and Europe, both in the wellness sector and in certain regulated medical situations. However, a misconception persists: that CBD is "mild" and therefore inherently free of interactions. In practice, recent data shows the opposite: drug interactions with cannabidiol can be clinically relevant, especially in patients taking multiple medications or those using treatments with a narrow therapeutic index.
For prescribers, the challenge is therefore not to systematically rule out CBD, but to identify high-risk situations, correctly interpret the level of evidence, and organize appropriate monitoring. The most credible signals currently concern the CYP2C19 and CYP3A4 pathways and P-glycoprotein, as well as certain well-documented combinations such as clobazam, valproate, and everolimus.
Why cannabidiol drug interactions deserve real attention
The key point to remember is simple: CBD is not "interaction-free." Recent reviews confirm that it can alter exposure to other medications, and its own concentration can also vary depending on co-prescriptions. In other words, we are talking about potentially bidirectional pharmacokinetic interactions, with concentrations increasing or decreasing depending on the other medication.
The most frequently observed mechanisms involve the inhibition of CYP2C19 and CYP3A4, as well as effects on P-gp. The review published in 2024 supports this view and proposes a clinical pharmacy approach based on monitoring and individualized dose adjustment. This approach is particularly useful in practice, as not all patients will have the same level of risk.
For healthcare professionals, this means that a quick medication history is not always sufficient. If a patient is already taking an antiepileptic, anticoagulant, immunosuppressant, or sedative, a structured medication review before initiating CBD is a sensible safety measure. This is especially important when the actual CBD dose, formulation, or product origin remains poorly documented.
What recent evidence and the FDA information leaflet for EPIDIOLEX say
The most robust regulatory element currently available is the FDA information leaflet for EPIDIOLEX, revised in June 2025. It states that cannabidiol may require a dose increase if administered with a strong CYP3A4 or CYP2C19 inducer, as these combinations can decrease CBD exposure. Conversely, certain co-administrations may lead to a dose reduction of sensitive medications.
The same information leaflet specifies that an adjustment may be necessary for certain substrates of CYP1A2, CYP2C8, UGT1A9, and for oral substrates of P-glycoprotein. It also highlights the importance of CYP2B6 and CYP2C19 substrates, for which a dosage modification may be beneficial. This framework is valuable for prescribers, as it goes beyond simple preclinical hypotheses.
However, a nuanced interpretation of the evidence is necessary. A 2024 systematic review on cannabinoid-CYP450 interactions concludes that the overall signal is consistent, but that human data remain limited, with only seven studies included and significant heterogeneity. In short, interactions do exist, but their exact magnitude is not yet fully quantified for all molecules and all patient profiles.
CYP2C19, CYP3A4 and P-gp: the most important pathways in practice
In routine practice, cannabidiol drug interactions primarily involve three pathways: CYP2C19, CYP3A4, and P-gp. CBD tends to inhibit CYP2C19 and CYP3A4, which can increase the exposure of co-administered drugs that use these pathways. This is one of the most consistent findings in recent reviews.
But the effect can also work in the opposite direction. Strong CYP3A4 inhibitors can increase CBD concentrations, while strong inducers can decrease them. This bidirectional nature is essential in practice, because the same combination can either increase side effects or reduce the expected efficacy of cannabidiol.
P-gp also warrants special attention, particularly for oral medications sensitive to this transporter. The FDA information leaflet mentions that a dose reduction may be necessary for certain oral P-gp substrates. In a frail, elderly, or polypharmaceutical patient, this information can make all the difference between a tolerable combination and excessive exposure.
Clobazam, valproate and everolimus: interactions you absolutely need to know
The interaction between CBD and clobazam is probably the most robust and useful to anticipate. It is well documented: co-administration significantly increases N-desmethylclobazam, the active metabolite of clobazam. In practice, this can increase sedation and other adverse effects, justifying close clinical monitoring and dose adjustment if necessary.
Valproate is another major area of concern, particularly regarding liver function. The FDA information leaflet warns that combining it with higher doses of CBD increases the risk of elevated transaminases. Furthermore, a recent review reports that co-administration of CBD has been associated with decreased exposure to valproate and its metabolite 4-ene-VPA, with frequent adverse events in the exposed group. This serves as a reminder that the risk is not merely theoretical.
Everolimus is also among the interactions explicitly recognized by the FDA. The package insert recommends a lower starting dose of oral everolimus when co-administered with CBD. For prescribers, this point is crucial: whenever an immunosuppressant or a treatment with a narrow therapeutic index is involved, initiating cannabidiol should be considered a true act of supervised co-prescription.
Sedation, liver, and clinical safety: risks that should not be underestimated
Beyond enzymes, pharmacodynamic interactions are very important. Drowsiness and sedation are signals that should not be underestimated, especially when CBD is combined with other central nervous system depressants. The FDA information leaflet recommends monitoring for these symptoms and advising patients about driving and operating machinery.
The risk of liver damage warrants particular attention. Before initiating EPIDIOLEX, the FDA recommends measuring ALT, AST, and total bilirubin due to the risk of hepatocellular injury. This risk appears to increase with certain combinations, particularly valproate, and with higher doses of CBD. Close monitoring of blood products after initiation and during dose increases is therefore a sensible precaution.
During consultations, it's helpful to explain to patients that "natural" doesn't mean "neutral." Even when used as a wellness product, CBD can interact with common or specialized medications. This explanation is especially important when patients purchase products whose actual composition, concentration, or the presence of other cannabinoids isn't fully known.
Anticoagulants, antiepileptics and other sensitive classes
Regarding warfarin and anticoagulants, caution is advised, but the level of evidence remains insufficient. A systematic review of anticoagulants and cannabinoids concludes that the available data primarily justify a targeted interaction trial with warfarin, as clinical evidence is limited and often derived from high-dose exposures. Therefore, we should neither overreact without solid evidence nor downplay the potential risks of this combination.
Antiepileptic drugs remain a particularly sensitive class, as they often have a narrow therapeutic index, multiple concomitant medications, and require pharmacokinetic stability. As soon as a patient is already receiving an antiepileptic regimen, CBD should trigger a formal review of their treatments, with particular attention to clobazam, valproate, and other CYP2C19 or CYP3A4 substrates.
Other classes of drugs can also pose a problem, including sedatives, certain immunosuppressants, and P-gp-transported medications. In these situations, the useful principle is not automatic prohibition, but anticipation. The more sensitive the co-administered drug is to changes in concentration, the more the prescriber must document, monitor, and reassess the situation rapidly after the introduction of CBD.
Practical advice for prescribers in consultation
Recent reviews consistently point to three simple actions: screening for co-medications, clinical and laboratory monitoring, and the use of therapeutic drug monitoring when available. This strategy is realistic and applicable in most healthcare settings, including general practice, neurology, and clinical pharmacy.
In practical terms, it's helpful to document the actual CBD dose, the formulation used, the frequency of use, and the product's origin. This is crucial because not all cannabidiol products are created equal. Variations in concentration, the presence of other cannabinoids, or potential contaminants can alter the interaction profile and complicate the interpretation of observed effects.
Finally, early reassessment after initiation or dose escalation is often the best protection. If the patient experiences increased drowsiness, abnormal laboratory results, a change in the effectiveness of their usual treatment, or unusual signs, a potential interaction should be considered. In practice, the recent consensus is clear: the most credible and useful interactions to anticipate involve clobazam, valproate, everolimus, and drugs metabolized by CYP2C19 or CYP3A4.
In summary, understanding the drug interactions of cannabidiol has become essential for modern and safe prescribing. The evidence is not perfect, but it is now consistent enough to justify active vigilance, especially regarding CYP2C19, CYP3A4, P-gp, clobazam, valproate, and everolimus.
The right approach for prescribers is neither excessive mistrust nor trivialization. It's a structured one: verifying co-treatments, precisely documenting the CBD product used, organizing clinical and biological monitoring, and then adjusting as needed. With this method, cannabidiol can be integrated more safely, transparently, and professionally into the patient care pathway.
